FDA delays decision on GSK, Valeant drug; Alimeria drug gets priority review status;

 @FierceBiotech: Novartis set to begin late-stage testing of blood thinner. Report | Follow @FierceBiotech

 @JohnCFierce: Be sure to check out our Top 10 Women in Biotech report. Already getting plenty of suggestions for next year. Add yours. | Follow @JohnCFierce

> GlaxoSmithKline and Valeant Pharmaceuticals may have to wait three more months for an FDA decision on their epilepsy treatment ezogabine. The FDA has moved the PDUFA date from August 30 to November 30. News

> Alimera Sciences late-stage diabetic macular edema drug Iluvien has received priority review status from the FDA. Article

> TheStreet takes a look at 21 drug facing near-term FDA decisions. Report

> Aveo Pharma's stock has shot up 40 percent in the last week as investors take notice of the company's progress on a Phase III kidney cancer drug. Story

> BTG has inked a $16.6 million deal to sell Nycomed's CroFab to treat patients with digoxin toxicity or overdose. Report

And Finally... Researchers have trained mice to detect the bird flu virus in migrating birds. Report

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.